GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

sipavibart   Click here for help

GtoPdb Ligand ID: 13905

Synonyms: AZD-3152 | AZD3152 | Kavigale®
Approved drug
sipavibart is an approved drug
Compound class: Antibody
Comment: Sipavibart (AZD3152) is an anti-SARS-CoV-2 monoclonal antibody that targets the virus' surface spike (S) protein [1,4]. This agent was designed as pre-exposure prophylaxis of COVID-19 in immunocompromised patients [3].
No information available.
Summary of Clinical Use Click here for help
Sipavibart (AZD3152) was approved for use in the EU in early 2025. It is also a component in the long-acting mixture AZD5156 (sipavibart + cilgavimab).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06057064 Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 Phase 2 Interventional AstraZeneca
NCT05648110 Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study Phase 2/Phase 3 Interventional AstraZeneca 2